Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 4.1    
  

	 	 	COMMON STOCK
	NUMBER

    HTC-	HealtheTech, Inc.	SHARES
	

 	
INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE	

 

	 	 	See reverse for certain definitions
	 	 	
CUSIP 422210 10 4

	This Certifies that	 	is the owner of

FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.001 PAR VALUE OF 

	
	 	HealtheTech, Inc.	 	

(herein called the "Corporation"), transferable on the books of the Corporation by the holder hereof in person or by duly authorized attorney upon surrender of this Certificate
properly endorsed. This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar.  

        WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers.  

 Dated:  

	 	SECRETARY	CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Countersigned and Registered:

AMERICAN STOCK TRANSFER & TRUST COMPANY

NEW YORK, N.Y.

Transfer Agent and Registrar

By

Authorized OFFICER  

HealtheTech, Inc.  

        A statement of the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and
the qualifications, limitations or restrictions of such preferences and/or rights as established, from time to time, by the Certificate of Incorporation of the Corporation and by any certificate of
determination, the number of shares constituting each class and series, and the designations thereof, may be obtained by the holder hereof upon request and without charge at the principal office of
the Corporation. 

        The
following abbreviations, when used in the inscription on the face of this Certificate, shall be construed as though they were written out in full according to applicable laws or
regulations: 

	TEN COM	 	—	 	as tenants in common	 	UNIF GIFT MIN ACT—	 	........................	 	Custodian	 	........................
	TEN ENT	 	—	 	as tenants by the entireties	 	 	 	(Cust)	 	 	 	(Minor)
	JT TEN	 	—	 	as joint tenants with right of survivorship and not as tenants in common	 	 	 	under Uniform Gifts to Minors
	COM PROP	 	—	 	as community property	 	 	 	Act........................

(State)
	 	 	 	 	 	 	UNIF TRF MIN ACT—	 	........................	 	Custodian (until age........................)

(Cust)
	 	 	 	 	 	 	 	 	........................under Uniform Transfers

(Minor)
	 	 	 	 	 	 	 	 	to Minors Act........................

(State)

Additional abbreviations may also be used though not in the above list. 

	
 PLEASE INSERT SOCIAL SECURITY OR OTHER

IDENTIFYING NUMBER OF ASSIGNEE
	 

	For value received	 	
	 	hereby sell, assign and transfer

	unto	 	
(Please print or typewrite name and address including postal zip code of assignee)
	

	

	

	
 	

Shares

of
the common stock represented by the within Certificate and do hereby irrevocably constitute and

	appoint	 	
	 	Attorney

to
transfer the said stock on the books of the within-named Corporation with full power of substitution in the premises. 

	 	Dated:	
	 	

	

 	

 	

 	
 	

NOTICE: THE SIGNATURE(S) TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME(S) AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE
WHATEVER.

SIGNATURE GUARANTEED:  

	
 THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION
PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15.
	

KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN, MUTILATED OR DESTROYED, THE CORPORATION WILL REQUIRE A BOND OF INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT CERTIFICATE.

QuickLinks

EXHIBIT 4.1QuickLinks
 -- Click here to rapidly navigate through this document

 
 

EXHIBIT 10.9    
  

 
 

ASSIGNMENT AGREEMENT    
  

        THIS ASSIGNMENT AGREEMENT ("Agreement") is made as of May 22, 2002 (the "Effective Date") by and between HealtheTech, a corporation organized and existing
under the laws of Delaware, having an office located at 523 Park Point Drive, Golden, CO 80401 ("Assignee") and Dr. James R. Mault, MD, an individual residing at 30589 Monarch Court, Evergreen,
CO 80439 ("Mault"). 

 
 

BACKGROUND    
  

        WHEREAS, Assignee and Mault previously entered into an Amended and Restated License Agreement dated December 10, 1999 (the "License Agreement") for certain
patents and patent applications, that include the Previously Assigned Patents (the "Licensed Patents"); and 

        WHEREAS,
Assignee is desirous of acquiring the entire right, title and interest in and to the Licensed Patents and other patents and patent applications owned or controlled by Mault,
including those patents and patent applications listed on Exhibit A ("Listed Patents"), the inventions disclosed therein, and in and to all embodiments of such inventions, heretofore conceived,
made or discovered jointly or severally by Mault (collectively the "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United
States and foreign countries (all the foregoing being collectively termed the "Patents"); and 

        WHEREAS,
Assignee agrees to pay Mault certain consideration for such Patents including the potential payment of royalties on Net Sales by Assignee of devices that measure cardiac output
in volume per unit of time that incorporate the Inventions protected by the Patents ("Products"), if such Products are ever sold, on the terms and conditions set forth below. 

        NOW,
THEREFORE, in consideration of the mutual covenants and promises contained herein, the parties hereto agree as follows: 

 
 

ARTICLE 1.    
    
    ASSIGNMENT    
  

        1.1    Assignment.    Mault does hereby sell, assign, transfer and convey unto the Assignee the entire right, title
and interest (a) in and to the Patents; (b) in and to all rights to apply for foreign patents on the Patents pursuant to the International Convention for the Protection of Industrial
Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on the Patents in the United States or any foreign country, including each and every
application filed and each and every patent granted on any application which is a divisional, substitution, continuation, or continuation-in-part of any of said applications;
and (d) in and to each and every reissue or extensions of any of said patents. 

        1.2    Cooperation.    Mault hereby covenants and agrees to cooperate with the Assignee to enable the Assignee to
enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by Mault shall include prompt production of pertinent facts and
documents, giving of testimony, execution of assignments, petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the
Assignee (a) for perfecting in the Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications that cover the Patents; (c) for filing and
prosecuting substitute, divisional, continuing or additional applications covering the Patents; (d) for filing and prosecuting applications for reissuance of any of the Patents; (e) for
interference or other priority proceedings involving the Patents; and (f) for legal proceedings involving the Patents, including without limitation reissues and reexaminations, opposition
proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by Mault in providing such
cooperation shall be paid for by the Assignee. 

 

        1.3    Termination of Amended and Restated License Agreement.    Assignee and Mault agree that the License Agreement
is terminated upon payment of the Assignment Fee as designated in Section 2.1.3.
Termination of the License Agreement does not relieve Assignee or Mault of obligations under the License Agreement that subsist or are to be performed after the termination of the License Agreement by
its own terms. 

 
 

ARTICLE 2.    
    
    CONSIDERATION    
  

        2.1    Consideration.    As total consideration for the rights title, and interest granted herein, Assignee agrees to
pay Mault as follows: 

        2.1.1    Mault Assignment Fee.    Assignee shall pay to Mault the sum of One Million Seven Hundred and Fifty Hundred
Thousand Dollars ($1,750,000). 

        2.1.2    Mault Contingent Royalty Payments.    Assignee shall pay to Mault the following payments contingent upon
Assignee making sales of Products: 

        (a)  Three
Percent (3.0%) of Net Sales for the first One Hundred Million Dollars ($100,000,000) of Cumulative Sales. 

        (b)  Two
Percent (2.0%) of Net Sales for Cumulative Sales ranging from One Hundred Million Dollars ($100,000,000) to Two Hundred Million Dollars ($200,000,000). 

        (c)  One
Percent (1.0%) of Net Sales for Cumulative Sales ranging from Two Hundred Million Dollars ($200,000,000) to Three Hundred Million Dollars ($300,000,000). 

        (d)  No
further payments will be due to Mault under this Section 2.1.2 once Cumulative Sales have exceeded Three Hundred Million Dollars ($300,000,000). 

        2.1.3    Payment Timing.    Payment under Section 2.1.1 shall be made on the earliest of (i) within four
(4) business days of Assignee receipt of funds from an initial public offering by Assignee, (ii) within four
(4) business days of event whereby there is a Change of Control of Assignee, or (iii) January 1, 2003. Payments under Section 2.1.2 shall be made within
forty-five (45) days of the end of the calendar quarter in which the Net Sales of Products, to which the payments relate, have occurred. 

        2.1.4    Definitions.    In this Agreement, "Valid Claim" shall mean a claim of an issued and unexpired patent or a
claim of a pending patent application which has not been held unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction and has not been admitted to be
invalid or unenforceable through reissue, re-examination, disclaimer or otherwise; provided, however, that if any holding of invalidity, unenforceability or unpatentability is later
reversed by a court or agency with overriding authority, the relevant claim shall be reinstated as a Valid Claim hereunder with respect to sales made after the date of such reversal. Notwithstanding
the foregoing provisions of this Section 2.1.4, if a claim of a pending patent application has not issued as a claim of an issued patent, within five (5) years after the date from which
such claim takes priority, such pending claim shall not be a Valid Claim for purposes of this Agreement unless and until the patent is issued including such claim. In this Agreement, "Net Sales" shall
mean amounts actually received by Assignee with respect to sales of products covered by a Valid Claim to independent third parties, less: (i) rebates, credits and cash, trade and quantity
discounts, actually taken, (ii) excise taxes, sales, use, value added, and other consumption taxes and other compulsory payments to governmental authorities, actually paid, (iii) the
cost of shipping packages and packing, if billed separately, (iv) insurance costs and outbound transportation charges prepaid or allowed, (v) import and/or export duties and tariffs
actually paid, (vi) amounts allowed or credited due to returns or uncollectable amounts. In this Agreement, "Cumulative Sales" shall 

2

 

mean the total Net Sales after the Effective Date of any Products covered by a Valid Claim of a Patent. In this agreement, "change of control" shall be defined as provided in Exhibit B. 

 
 

ARTICLE 3.    
    
    REPRESENTATIONS AND WARRANTIES, INDEMNITEES    
  

        3.1    Mault.    Mault hereby represents and warrants that: (i) Mault is the sole and exclusive owner of all
right, title and interest in and to the Patents; (iv) Mault has the right to grant the rights granted herein; (v) the Patents are free and clear of any lien, encumbrance, security
interest or restriction on license; (vi) Mault has not previously granted, and will not grant, any right, license or interest in or to the Patents, or any portion thereof, inconsistent with the
rights granted to Assignee herein; (viii) there are no threatened or pending actions, suits, investigations, claims or proceedings in any way relating to the Patents. 

        3.2    Development of Products.    Mault and Assignee hereby acknowledge and agree that Assignee shall have no duty or
obligation to develop and sell Products, and that Assignee may elect to develop cardiac output devices or other products that do not incorporate the Inventions. Mault agrees that any decision relating
to whether Assignee shall expend development resources to create any Products, and the timing of any such decision and the timing and amount of any such expenditure of resources, shall be at the sole
discretion of Assignee. If Mault is an employee, Director or consultant of Assignee at the time that these decisions are considered by Assignee, Mault hereby waives any power or authority to make such
decisions on behalf of Assignee. 

        3.3    Assignee Indemnity.    Assignee shall defend and hold Mault, but no other third parties, harmless as against
any judgments, fees, expenses, or other costs arising from or incidental to any lawsuit, claim, demand or other action (a "Liability") brought by a third party, whether or not Mault is named as a
party defendant in any lawsuit, except to the extent such Liability is caused by the negligence or willful misconduct of Mault. 

        3.4    Procedure.    In the event that Mault intends to claim indemnification under Section 3.3, he shall
promptly notify Assignee in writing of such potential Liability. Assignee shall have the right to control the defense thereof. Mault shall cooperate fully with Assignee and its legal representatives
in the investigation and conduct of any Liability covered by Section 3.3. Notwithstanding the foregoing, Assignee shall have no indemnity obligations for any claim if Mault makes any admission,
settlement or other communication regarding such claim without the prior written consent of Assignee. 

 
 

ARTICLE 4.    
    
    GENERAL    
  

        4.1    Governing Law.    This Agreement shall be governed by and construed in accordance with the laws of the State of
Colorado, without reference to principles of conflicts of laws. 

        4.2    Independent Contractors.    The relationship of the parties hereto is that of independent contractors. The
parties hereto are not deemed to be agents, partners or joint ventures of the other for any purpose as a result of this Agreement or the transactions contemplated thereby. 

        4.3    Notices.    Any required notices hereunder shall be given in writing by certified mail or overnight express
delivery service at the address of each party set forth above, or to such other address as either party may indicate on its behalf by written notice. Notice shall be deemed served when delivered or,
if delivery is not accomplished by reason or some fault of the addressee, when tendered. 

        4.4    Force Majeure.    Neither party shall lose any rights hereunder or be liable to the other party for damages or
losses (except for payment obligations) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, Act of God, earthquake, flood, lockout, 

3

 

embargo, governmental acts or orders or restrictions, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional
conduct or misconduct of the nonperforming party and the nonperforming party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party
be required to settle any labor dispute or disturbance. 

        4.5    Compliance with Laws.    Each party shall furnish to the other party any information related to the subject
matter of this Agreement requested or required by that party during the term of this Agreement or any extensions hereof to enable that party to comply with the requirements of any U.S. or foreign
federal, state and/or government agency. 

        4.6    LIMITATION OF LIABILITY.    NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF THE PERFORMANCE OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

        4.7    Further Assurances.    At any time or from time to time on and after the date of this Agreement, Mault shall at
the written request of Assignee (i) deliver to Assignee such records, data or other documents consistent with the provisions of this Agreement, (ii) execute, and deliver or cause to be
delivered, all such consents, documents or further instruments of transfer or license, and (iii) take or cause to be taken all such actions, as Assignee may reasonably deem necessary or
desirable in order for Assignee to obtain the full benefits of this Agreement and the transactions contemplated hereby. 

        4.8    Inuring, Binding.    The terms and covenants of this Agreement shall inure to the benefit of the Assignee, its
successors, assigns and other legal representatives, and shall be binding upon Mault, his heirs, legal representatives and assigns. 

        4.9    Severability.    In the event that any provisions of this Agreement are determined to be invalid or
unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. The parties shall in good faith negotiate a substitute
clause for any provision declared invalid or unenforceable, which shall most nearly approximate the intent of the parties in entering this Agreement. 

        4.10    Waiver.    The failure of a party to enforce any provision of the Agreement shall not be construed to be a
waiver of the right of such party to thereafter enforce that provision or any other provision or right. 

        4.11    Entire Agreement; Amendment.    This Agreement sets forth the entire agreement and understanding of the
parties with respect to the subject matter hereof, and supersedes all prior discussions, agreements and writings in relating thereto. This Agreement may not be altered, amended or modified in any way
except by a writing signed by both parties. 

        4.12    Counterparts.    This Agreement may be executed in two counterparts, each of which shall be deemed an original
and which together shall constitute one instrument. 

        IN
WITNESS WHEREOF, Assignee and Mault have executed this Agreement by their respective duly authorized representatives. 

	ASSIGNEE	 	MAULT
	

By:	
 	

/s/  NOEL L. JOHNSON      
	
 	

By:	
 	

/s/  JAMES R. MAULT, MD      

	

Name:	
 	

Noel L. Johnson	
 	

Name:	
 	

James R. Mault, MD
	Title:	 	President and COO

HealtheTech, Inc.	 	 	 	5/23/02

4

   Exhibit A: Patents to be Assigned  

	FILE NO.
 
	 	TITLE
 
	 	COUNTRY
	 	SERIAL NO./

PATENT NO.
	 	FILING

DATE
	 	ISSUE

DATE

	MJA-10102/03	 	METABOLIC GAS EXCHANGE AND NONINVASIVE CARDIAC OUTPUT MONITOR	 	US	 	08/814,677/5836300	 	3/11/97	 	11/17/98
	

MJA-10103/03	
 	

METABOLIC GAS EXCHANGE AND NONINVASIVE CARDIAC OUTPUT MONITOR	
 	

US	
 	

09/191,782/6135107	
 	

11/13/98	
 	

10/24/00
	

MJA-10133/03	
 	

METABOLIC GAS EXCHANGE AND NONINVASIVE CARDIAC OUTPUT MONITOR	
 	

EP	
 	

98911713	
 	

3/13/98	
 	

 
	

MJA-10143/03	
 	

METABOLIC GAS EXCHANGE AND NONINVASIVE CARDIAC OUTPUT MONITOR	
 	

JP	
 	

2000-535399	
 	

3/13/98	
 	

 
	

MJA-10154/03	
 	

METABOLIC GAS EXCHANGE AND NONINVASIVE CARDIAC OUTPUT MONITOR	
 	

TW	
 	

87104778/NI-102571	
 	

3/13/98	
 	

8/19/99
	

MJA-10402/03	
 	

RESPIRATORY CALORIMETER	
 	

US	
 	

09/008,435/6309360	
 	

1/16/98	
 	

10/30/01
	

MJA-10403/03	
 	

RESPIRATORY CALORIMETER	
 	

US	
 	

10/057,651	
 	

10/29/01	
 	

 
	

MJA-10426/03	
 	

RESPIRATORY CALORIMETER	
 	

CA	
 	

2283820	
 	

3/13/98	
 	

 
	

MJA-10433/03	
 	

RESPIRATORY CALORIMETER	
 	

EP	
 	

98910480.7	
 	

3/13/98	
 	

 
	

MJA-10443/03	
 	

RESPIRATORY CALORIMETER	
 	

JP	
 	

10-540750	
 	

3/13/98	
 	

 
	

MJA-10454/03	
 	

RESPIRATORY CALORIMETER	
 	

TW	
 	

87103952/NI-104808	
 	

3/17/98	
 	

7/11/99
	

MJA-10702/03	
 	

METABOLIC CALORIMETER EMPLOYING RESPIRATORY GAS ANALYSIS	
 	

US	
 	

09/601,589	
 	

8/4/00	
 	

 
	
 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 

5

 

	

MJA-10726/03	
 	

METABOLIC CALORIMETER EMPLOYING RESPIRATORY GAS ANALYSIS	
 	

CA	
 	

2320238	
 	

2/5/99	
 	

 
	

MJA-10733/03	
 	

METABOLIC CALORIMETER EMPLOYING RESPIRATORY GAS ANALYSIS	
 	

EP	
 	

99906742.4	
 	

2/5/99	
 	

 
	

MJA-10743/03	
 	

METABOLIC CALORIMETER EMPLOYING RESPIRATORY GAS ANALYSIS	
 	

JP	
 	

2000-530144	
 	

2/5/99	
 	

 
	

MJA-11226/03	
 	

OXYGEN CONSUMPTION METER (calorimeter)	
 	

CA	
 	

2112382/2112382	
 	

6/27/91	
 	

9/4/01
	

MJA-11233/03	
 	

OXYGEN CONSUMPTION METER (calorimeter)	
 	

EP	
 	

591217	
 	

7/27/91	
 	

4/19/00
	

MJA-11243/03	
 	

OXYGEN CONSUMPTION METER	
 	

JP	
 	

4-503127/3020606	
 	

6/27/91	
 	

1/14/00
	

MJA-11303/03	
 	

RESPIRATORY CALORIMETER WITH BIDIRECTIONAL FLOW MONITORS FOR CALCULATING OF OXYGEN CONSUMPTION AND CARBON DIOXIDE PRODUCTION	
 	

US	
 	

07/814,829/5178155	
 	

12/31/91	
 	

1/12/93
	

MJA-11326/03	
 	

RESPIRATORY CALORIMETER WITH BIDIRECTIONAL FLOW MONITORS FOR CALCULATING OF OXYGEN CONSUMPTION AND CO2 PRODUCTION	
 	

CA	
 	

2126875	
 	

12/29/92	
 	

 
	

MJA-11333/03	
 	

RESPIRATORY CALORIMETER WITH BIDIRECTIONAL FLOW MONITORS	
 	

EP	
 	

93902793.4/639951	
 	

12/29/92	
 	

5/12/99
	
 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 

6

 

	

MJA-11343/03	
 	

RESPIRATORY CALORIMETER WITH BIDIRECTIONAL FLOW MONITORS	
 	

JP	
 	

5-511931/3043810	
 	

12/29/92	
 	

3/10/00
	

MJA-11602/03	
 	

METHOD AND APPARATUS FOR RESPIRATORY GAS ANALYSIS EMPLOYING MEASUREMENT OF EXPIRED GAS MASS	
 	

US	
 	

09/674,897/6277645	
 	

11/7/00	
 	

8/21/01
	

MJA-11603/03	
 	

METHOD AND APPARATUS FOR RESPIRATORY GAS ANALYSIS EMPLOYING MEASUREMENT OF EXPIRED GAS MASS	
 	

US	
 	

09/933,515	
 	

8/20/01	
 	

 
	

MJA-11626/03	
 	

METHOD AND APPARATUS FOR RESPIRATORY GAS ANALYSIS EMPLOYING MEASUREMENT OF EXPIRED GAS MASS	
 	

CA	
 	

2338998	
 	

8/3/99	
 	

 
	

MJA-11633/03	
 	

METHOD AND APPARATUS FOR RESPIRATORY GAS ANALYSIS EMPLOYING MEASUREMENT OF EXPIRED GAS MASS	
 	

EP	
 	

99939677.3	
 	

8/3/99	
 	

 
	

MJA-11643/03	
 	

METHOD AND APPARATUS FOR RESPIRATORY GAS ANALYSIS EMPLOYING MEASUREMENT OF EXPIRED GAS MASS	
 	

JP	
 	

2001-563186	
 	

8/3/99	
 	

 
	

MJA-12202/03	
 	

METHOD AND APPARATUS FOR THE NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT	
 	

US	
 	

09/674,898	
 	

11/7/00	
 	

 
	

MJA-12226/03	
 	

METHOD AND APPARATUS FOR THE NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT	
 	

CA	
 	

2351639	
 	

11/17/99	
 	

 
	
 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 

7

 

	

MJA-12233/03	
 	

METHOD AND APPARATUS FOR THE NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT	
 	

EP	
 	

99960446.5	
 	

11/17/99	
 	

 
	

MJA-12243/03	
 	

METHOD AND APPARATUS FOR THE NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT	
 	

JP	
 	

2000-581933	
 	

11/17/99	
 	

 
	

MJA-12402/03	
 	

AIRWAY-BASED CARDIAC OUTPUT MONITOR AND METHODS FOR USING SAME	
 	

US	
 	

09/674,899	
 	

11/7/00	
 	

 
	

MJA-12426/03	
 	

AIRWAY-BASED CARDIAC OUTPUT MONITOR AND METHODS FOR USING SAME	
 	

CA	
 	

 	
 	

 	
 	

 
	

MJA-12433/03	
 	

AIRWAY-BASED CARDIAC OUTPUT MONITOR AND METHODS FOR USING SAME	
 	

EP	
 	

932242.1	
 	

5/10/00	
 	

 
	

MJA-12443/03	
 	

AIRWAY-BASED CARDIAC OUTPUT MONITOR AND METHODS FOR USING SAME	
 	

JP	
 	

2000-616668	
 	

5/10/00	
 	

 
	

MJA-19002/03	
 	

RESPIRATORY CALORIMETER	
 	

US	
 	

213184/4917108	
 	

6/29/88	
 	

4/17/90
	

MJA-19003/03	
 	

OXYGEN CONSUMPTION METER (calorimeter)	
 	

US	
 	

07/368,947/5038792	
 	

6/23/89	
 	

8/13/91
	

MJA-19004/03	
 	

RESPIRATORY CALORIMETER WITH BIDIRECTIONAL FLOW MONITOR	
 	

US	
 	

07/726,922/5179958	
 	

7/8/91	
 	

1/19/93
	

JA-19026/03	
 	

02 CONSUMPT. METER	
 	

CA	
 	

604468/1332004	
 	

6/29/89	
 	

9/13/94
	
 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 

8

 

	

MJA-24102/03	
 	

A SYSTEM AND METHOD OF METABOLIC RATE MEASUREMENT	
 	

US	
 	

10/090,984	
 	

3/4/02	
 	

 
	

MJA-26080/03	
 	

HEALTH IMPROVEMENT SYSTEM AND METHOD	
 	

US	
 	

60/362,030	
 	

3/6/02	
 	

 
	

MJA-26518/03	
 	

IMPROVED SYSTEMS AND METHODS FOR DRUG ADMINISTRATION	
 	

US	
 	

 	
 	

4/1/02	
 	

 

9

 

 Exhibit B:  

        "Change of Control" means the occurrence of any of the following events: 

        (a)  Any
"person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), excluding existing beneficial owners as of the date
of this Letter, is or becomes the "beneficial owner" (as defined in Section 13d-3 of said Act), directly or indirectly, of securities of the Assignee representing 50% or more of the
total voting power represented by the Assignee's then outstanding voting securities, excluding conversion of any convertible securities issued as of the date of this Letter; 

        (b)  The
composition of the Board of Directors changes during any period of 36 months such that individuals who at the beginning of the period were members of the
Board of Directors (the "Continuing Directors") cease for any reason to constitute at least a majority thereof; unless at least 662/3% of the Continuing Directors has either
(i) approved the election of the new Directors, (ii) if the election of the new Directors is voted on by shareholders, recommended that the shareholders vote for approval, or
(iii) otherwise determined that such change in composition does not constitute a Change of Control, even if the Continuing Directors do not constitute a quorum of the whole Board (it being
understood that this requirement shall not be capable of satisfaction unless there is at least one Continuing Director); 

        (c)  The
shareholders of the Assignee approve a merger or consolidation of the Assignee with any other corporation, other than a merger or consolidation which would result in
the voting securities of the Assignee outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving
entity) at least 50% of the total voting power represented by the voting securities of the Assignee or such surviving entity outstanding immediately after such merger or consolidation, or the
shareholders of the Assignee approve a plan of complete liquidation of the Assignee or an agreement for the sale or disposition by the Assignee of all or substantially all of the Assignee's assets; 

        (d)  Any
other provision of this subsection notwithstanding, the term Change of Control shall not include either of the following events undertaken at the election of the
Assignee: 

        (i)    Any
transaction, the sole purpose of which is to change the state of the Assignee's incorporation; or 

        (ii)  A
transaction, the result of which is to sell all or substantially all of the assets of the Assignee to another corporation (the "surviving corporation") provided that
the surviving corporation is owned directly or indirectly by the shareholders of the Assignee immediately following such transaction in substantially the same proportions as their ownership of the
Assignee's common stock immediately preceding such transaction. 

10

QuickLinks

EXHIBIT 10.9

ASSIGNMENT AGREEMENT

BACKGROUND

ARTICLE 1. ASSIGNMENT

ARTICLE 2. CONSIDERATION

ARTICLE 3. REPRESENTATIONS AND WARRANTIES, INDEMNITEES

ARTICLE 4. GENERAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00039-of-00352.parquet"}]]